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The tumour–stroma ratio in colon cancer: the biological role and its prognostic impact
The tumour microenvironment consists of a complex
mixture of non-neoplastic cells, including fibroblasts,
immune cells and endothelial cells embedded in the
proteins of the extracellular matrix. The tumour
microenvironment plays an active role in tumour
behaviour. By interacting with cancer cells, it influ-
ences disease progression and the metastatic capacity
of the tumour. Tumours with a high amount of
stroma correspond to poor patient prognosis. The
tumour–stroma ratio (TSR) is a strong independent
prognostic tool in colon cancer and provides addi-
tional value to the current clinically used tumour–
node–metastasis classification. The TSR is assessed on
conventional haematoxylin and eosin-stained paraffin
sections at the invasive front of the tumour. Here we
review studies demonstrating the prognostic signifi-
cance of the TSR in solid epithelial tumours with a
focus on colon cancer. Moreover, the biological role
of the tumour microenvironment during tumour pro-
gression and invasion will be discussed, as well as the
attempts to target the tumour stroma for therapeutic
purposes. We suggest that the TSR can be imple-
mented with little effort and without additional costs
in current routine pathology diagnostics owing to its
simplicity and reliability.
Keywords: colon cancer, TNM classification, tumour microenvironment, tumour–stroma ratio
Introduction
The tumour–node–metastasis (TNM) classification of
the American Joint Committee on Cancer (AJCC) is
most commonly used in clinical decision-making to
define the extent of tumour progression. The TNM
provides prognostic information and aids in treatment
decision.1–3 However, clinical outcome varies between
patients with colon cancer within the same TNM
stage. For instance, 5–25% of stage II patients still
develop recurrence of disease within 5 years. In
addition, patients with stage IIB have a worse prog-
nosis than stage IIIA colon cancer patients, leading
in some cases to undertreatment of stage II patients
and overtreatment of stage III patients.4
The current TNM classification is based on anatomi-
cal extent, but there is a need for additional prognos-
tic and/or predictive markers.5 Additional biomarkers
have been proposed based on tumour cell characteris-
tics, including tumour cell morphology, molecular
pathways, genetic mutations, cell of origin and gene
expression (see below), as well as the tumour immune
response (Figure 1).6 A drawback of some of these is
the high cost of genetic and transcriptomic data,
whereas standard pathological assessment using
microscopical analysis is fast, cheap and reliable. A
biomarker that is based on microscopical analysis is
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therefore desirable. The tumour–stroma ratio (TSR),
also referred to as the tumour–stroma percentage, is
assessed on conventional haematoxylin and eosin
(H&E)-stained paraffin sections at the invasive front of
the tumour and links patients with high stromal reac-
tion to worse prognosis. The TSR has been reported as
a strong independent prognostic tool in colon cancer
as well as in other epithelial cancers.7–24 The impor-
tance of the tumour stroma is emphasized in the
recent consensus molecular subtypes (CMS) classifica-
tion of colorectal cancer (CRC). The CMS1–4 was
assessed based on transcriptome analysis of CRC.
Tumours classified as CMS4 were characterized by a
worse prognosis, activated transforming growth factor
(TGF)-b and increased stromal content.6 Two studies
showed that stromal cells contribute extensively to
the mesenchymal phenotype of aggressive CRC cate-
gorized as CMS4.25,26
The tumour stroma consists of a complex mixture
of non-neoplastic cells including fibroblasts, immune
cells and endothelial cells embedded in the proteins of
the extracellular matrix (ECM). The activated form of
fibroblasts, the so-called cancer-associated fibroblasts
(CAFs), are the predominant cell type in the tumour
stroma and are involved in tumour progression and
invasion. Stromal cells supply the tumour with
growth factors, cytokines and metabolites and stimu-
late blood vessel formation (Figure 2). In this way the
tumour stroma contributes to tumorigenesis and
induction of EMT in cancer cells.27 This explains why
a tumour with a high stromal content reflects a pro-
metastatic phenotype of cancer cells and that the
interaction between cancer and stromal cells affects
disease outcome and response to therapy.28,29 How-
ever, the biological mechanism of cancer cells recruit-
ing and activating fibroblasts is not understood
completely.
Here we will give an overview of the prognostic
value of the TSR in colon cancer as well as in other
epithelial cancer types. Moreover, the biological role
of the tumour microenvironment during tumour pro-
gression and invasion will be discussed, as well as the
attempts to target the tumour stroma for therapeutic
purposes.
Methodology of TSR
The TSR is evaluated based on routine 5-lm thick
H&E sections using conventional microscopy. The
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Figure 1. Distinct colorectal cancer classifications based on tumour compartment and tumour microenvironment.
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intratumoural stroma formation is assessed at the
invasive part of the tumour, which is most determi-
native for tumour progression. This was decided in a
study of colon cancers in which multiple H&E slides
from different areas of the tumour were available for
scoring. Heterogeneity in the percentage of stroma
was observed throughout the tumour and the highest
stroma percentages were observed in the tumour
areas with the deepest invasion in the bowel wall
(higher T-stage).8 For retrospective studies, the slide
with the most invasive part of the tumour generally
corresponds to the slide used in routine pathology to
determine the T-status and is indicated in the pathol-
ogy report.
Areas covered with the largest amount of stroma
are selected using a 92.5 or 95 objective. Using the
910 objective, image fields are scored in increments
of 10%. Tumour cells are to be present at the four
borders of the selected image field (Figure 3). Identify-
ing one single image-field with high stroma content
is decisive for a final stroma classification. A statisti-
cally determined cut-off value of 50% distinguishes
between stroma-high (>50%) and stroma-low (≤50%)
patients.8 Using these criteria, scoring of the TSR is
relatively easy, resulting in a low interobserver varia-
tion in different published validation studies
(Table 1).7–12,30
The TSR is estimated adequately in resection speci-
mens of patients operated for a primary epithelial
tumour, including mucinous tumours. However,
patients pretreated with chemo- and/or radiotherapy
are generally excluded from TSR scoring. Therapy
induces changes in tissue arrangements as cell mor-
phology and composition, resulting in stromal forma-
tion surrounding the tumour.31–34 Analysing the
TSR in biopsies to assess the prognostic value of the
patient is an alternative for patients pretreated with
chemo- and/or radiotherapy (see below).
TSR, a prognostic factor in colon cancer
T S R I N P R I M A R Y C O L O N C A N C E R
Multiple studies, performed and validated by different
research groups, demonstrate that the TSR is a robust
prognostic factor in colon cancer. In 2007, Mesker
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Figure 2. A simplistic scheme of the direct and indirect effect of cancer-associated fibroblasts (CAFs) on cancer cells. The activation of CAFs
through transforming growth factor (TGF)-b and platelet-derived growth factor (PDGF) growth factors induce angiogenesis and reprogramme
immune cells in the tumour microenvironment and leads to cancer cell survival. Also, the secretion of cytokines and different soluble mole-
cules by CAFs induce cancer cell survival, epithelial–mesenchymal transition (EMT), stem cell properties and drug resistance in cancer cells.
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et al. developed the TSR for patients with stages I–III
disease, and found that patients with tumours with a
high stromal content had a significantly worse overall
survival (P < 0.001) and disease-free survival
(P < 0.001), independently of T-stage and N-stage.8
The studies by Huijbers et al., Park et al. and van Pelt
et al. found comparable results for overall and disease
free survival (n = 710, P = 0.002 and P < 0.001),
cancer-specific survival (n = 250, P = 0.009) and
disease-free survival (n = 102, P = 0.038), respec-
tively.7,10,11 West et al.’s research group used a semi-
automated method to investigate the prognostic value
of the relative proportion of tumour at the luminal
surface. Although a different method compared to the
TSR, they found a comparable cut-off value of 47%,
leading to similar results12 (Table 1). Both Park et al.
A
B
Figure 3. Examples of stroma-
low (A, 20% stroma) and
stroma-high (B, 90% stroma)
haematoxylin and eosin-
stained paraffin sections at the
most invasive part of primary
colon cancers.
Table 1. Characteristics of tumour stroma studies in colorectal cancer
Study Number of patients Stage Outcome [HR (95% CI)] Interobserver variation
Mesker et al., 2007 122 I–III OS: 3.74 (2.32–6.01), P < 0.001
DFS: 4.18 (2.63–6.65), P < 0.001
NS
Mesker et al., 2009 135 I–II OS: 2.73 (1.73–4.30), P < 0.001
DFS: 2.43 (1.55–3.82), P < 0.002
Κ = 0.6–0.7
(3 observers)
Huijbers et al., 2013 710 II–III OS: 1.71 (1.22–2.41), P = 0.002
DFS: 1.95 (1.45–2.61), P < 0.001
Κ = 0.89
West et al., 2010* 145 I–IV CSS: 2.09 (1.09–4.00), P = 0.017 Κ = 0.97
Park et al., 2014 250 I–III CCS: 1.84 (1.17–2.92), P = 0.009 Κ = 0.81
van Pelt et al., 2016 102 III DFS PT: 1.98 (1.04–3.77), P = 0.038
DFS PT+LNs: 2.85 (1.33–6.10), P = 0.007
Κ = 0.73
Hynes et al., 2017 445 II–III CSS: 1.45 (0.92–2.29)
OS: 1.49 (1.02–2.20)
Κ = 0.5–1.0
(4 observers)
NS, not stated; HR, hazard ratio; CI, confidence interval; OS, overall survival; DFS, disease-free survival; CSS, cancer-specific survival; PT,
primary tumour; LNs, lymph nodes.
*West et al. used a cut-off point of 47% with a semi-automated method.
© 2018 John Wiley & Sons Ltd, Histopathology, 73, 197–206.
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and West et al. included rectal cancer patients who
did not receive neoadjuvant therapy. However, their
results were comparable with studies investigating
only colon cancer patients (from caecum to sigmoid
colon).
The adverse prognostic impact of high tumour
stroma is observed in both early disease and
advanced colon cancer. As patients with stage II
colon cancer have highly variable outcomes, the
TSR is a useful tool to select patients who are at
risk of developing recurrence of disease or metas-
tases. Consequently, this subpopulation might also
be considered for adjuvant therapy, a decision based
currently on the American Society of Clinical Oncol-
ogy (ASCO) criteria including T4 tumour stage, the
number of lymph nodes examined (<10), poor
tumour differentiation, presence of lymphatic, vascu-
lar and/or perineural invasion and perforation of
the bowel wall. The study by Huijbers et al. investi-
gated the TSR next to the ASCO criteria to select
high-risk stage II colon cancer patients. They found
that the TSR improved the ASCO criteria and reclas-
sified 14% of the patients as high-risk, thereby drop-
ping the rate of undertreated patients from 6% to
4%.7 This suggests that adjuvant therapy might be
considered in stage II patients with high tumour
stroma content. Further research should assess the
effectiveness of adjuvant therapy in stroma-high
patients.
T S R I N M E T A S T A T I C L Y M P H N O D E S O F C O L O N
C A N C E R
The prognostic implications of metastatic lymph
nodes have been widely established. Lymph node-
negative patients have a 5-year survival rate of more
than 58% (stage IIC), decreasing to 35% when lymph
nodes are involved (stage IIIC).4
Although lymph node involvement has proved its
importance, all studies investigating the TSR in colon
cancer patients have found the TSR to be a prognos-
tic factor independent of the N-status.7,8,10–12 More-
over, evaluation of the TSR in metastatic lymph
nodes of stage III colon cancer patients has been
shown recently to be of additional prognostic value.
A strong heterogeneity of TSR between lymph nodes
of a single patient was observed, and it was found
that the presence of abundant stroma in at least one
lymph node already contributed significantly to the
prognostic information initially learned solely from
the primary tumour (P = 0.007).11 These findings
emphasize that not only the number of positive
lymph nodes but also the composition of the
microenvironment within the lymph node metastasis
is important for patient outcome.35
T S R I N P R E - O P E R A T I V E B I O P S I E S
As mentioned previously, patients pretreated with
chemo- and/or radiotherapy are not eligible for
tumour stroma scoring due to therapy-related stromal
formation. As a consequence, rectal cancer patients,
who often receive neoadjuvant therapy, are usually
excluded from TSR studies. Scoring the TSR on biop-
sies of neoadjuvantly treated patients might be a good
alternative, although the TSR cannot be determined
at the most invasive front. In oesophageal cancer, for
instance, TSR score assessed on biopsies was an inde-
pendent prognostic factor for survival, in line with
the TSR in primary tumours.36 The TSR scores of the
primary tumour and the matching presurgical biopsy
correlated in 81% of the cases. The remaining dis-
crepant scores were stroma-high primary tumours
while the matching biopsy was assessed as stroma-
low, thereby underestimating the TSR and leading to
false-negative selection. However, as the biopsies
showed a high correlation with matching resection
material, especially for stroma-high cases (100% cor-
relation), biopsies could be used for prediction of
patient outcome. Eventually, it would be of interest if
the TSR scores of biopsies could be used to predict
the response to neoadjuvant treatment.
The biological mechanism of the tumour
stroma in colon cancer
T H E T U M O U R M I C R O E N V I R O N M E N T F O R M A T I O N
A high stromal content is a reflection of the highly
activated interaction between tumour and stromal
cells. During tumour progression, specific molecular
changes in colon cancer cells cause the recruitment
and activation of surrounding stromal cells by releas-
ing soluble growth factors, metabolites and cyto-
kines.37 Two main cancer cell-secreted growth factors
are TGF-b and platelet-derived growth factor (PDGF),
which have been largely acknowledged to mediate
the conversion of normal fibroblasts into CAFs (Fig-
ure 2).37–39 Mitogenic factors secreted by fibroblasts
include hepatocyte growth factor,27 fibroblast growth
factors, epidermal growth factor family members and
chemokine ligand 12.40 In addition, a number of
studies analysing transcriptomic data have reported
that the activation level of CAFs present in the
tumour showed prognostic value in colorectal
cancer.26,41,42
© 2018 John Wiley & Sons Ltd, Histopathology, 73, 197–206.
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The TGF-b signalling pathway is considered a cen-
tral player during tumour progression. The pathway
exerts a dual role: its activation can function as a
tumour suppressor by inducing apoptosis in normal
cells and early stage cancers and can later promote
tumorigenesis. The paradox that high levels of TGF-
b1 correlate with poor prognosis can be explained
partially by the fact that the tumour stroma remains
highly responsive to the growth factor. TGF-b-acti-
vated CAFs secrete a range of growth factors that
support tumour growth and induce a mesenchymal
phenotype in cancer cells.37
T H E R O L E O F T H E T U M O U R M I C R O E N V I R O N M E N T
I N T U M O U R P R O G R E S S I O N
Various mechanisms have been proposed to explain
how the tumour microenvironment contributes to
tumour progression, tumour invasion and metastasis,
for instance by: (i) impacting the proliferation and
survival of cancer cells, (ii) increasing their stem-like
properties and favouring EMT,27,38,43 (iii) rewiring
the tumour metabolism40 and/or (iv) stimulating
metastatic dissemination (Figure 2). In-vivo studies
demonstrated that co-injection of cancer cells and
CAFs or mesenchymal stem cells lead to an increased
tumour growth, invasion and metastasis compared to
co-injection of cancer cells with normal fibrob-
lasts.44,45
The tumour stroma provides a nourishing environ-
ment that maintains cancer stem cells (CSCs) in a
tumour. CSCs are characterized by an activated Wnt
pathway and the nuclear translocation of the onco-
protein b-catenin. Vermeulen et al. showed that colon
cancer cells located at the tumour invasive front
acquire an increased stem-like state due to stromal
fibroblasts activating the Wnt pathway, compared to
cancer cells located in the central part of the tumour.
These results suggest that CAFs foster stemness of
cancer cells.27 Tumours with an increased number of
CSCs are predictive of a negative patient outcome due
to intratumoral heterogeneity.28,29 Furthermore,
stem-like properties acquired by premetastatic cancer
cells are linked to EMT induction, a process where
cancer cells lose epithelial characteristics and acquire
mesenchymal properties. It was found in several stud-
ies that the tumour stroma, in particular myofibrob-
lasts, can induce EMT in cancer cells via cell-to-cell
contact.45,46
In addition, soluble factors secreted by cancer cells
participate in the metabolic reprogramming of CAFs.
CAFs rely upon aerobic glycolysis, a metabolism com-
parable to that of highly proliferating cells. The
metabolic alteration in CAFs, in its turn, probably
promotes the cancer cell metabolic adaptation.47 The
tumour stroma can impact the aggressive behaviour
of cancer cells not only through cell–cell contact and
auto- and paracrine signalling but also through
mechanical pressure. Due to the abundant ECM and
the high number of CAFs, the tumour stroma forms a
physical barrier around the tumour that increases
the interstitial pressure and hypoxia in the tumour.
Cancer cells respond to hypoxic conditions through
the up-regulation of hypoxia-inducible factor 1a, a
master transcription factor that activates a whole
range of genes involved in angiogenesis, migration,
metabolism, tumour invasion and metastasis.48
T A R G E T I N G T H E S T R O M A L C O M P A R T M E N T
While tumour cells have been the main therapeutic
target in the past, different components of the tumour
microenvironment, such as immune cells and angio-
genesis, have been targeted recently. Based on the
understanding of the tumour stroma, oncogenic path-
ways activated in the tumour microenvironment,
CAF markers and their soluble molecules can be tar-
geted therapeutically.42 For instance, the TGF-b path-
way is highly increased in fibroblasts of stroma-high
tumours. Based on preclinical studies, different TGF-b
targeting agents were used in clinical trials, such as
the TGF-b receptor kinase inhibitor galunisertib (rec-
tal adenocarcinoma NCT02688712, Phase II), show-
ing both negative as well as positive results. The dual
function of the signalling pathway makes it a chal-
lenging target.49 For an extensive summary of TGF-b
targeting drugs, see the review by Colak et al.50
Another activated signalling pathway is the PDGFR
pathway which can be targeted by the imatinib anti-
cancer drug. The ongoing ImPACCT clinical trial
investigates the efficacy of the drug in patients with
colon cancer characterised as CMS4, described in
Ubink et al.51
Therapeutically targeting CAFs can also promote
anti-tumour response, and it could be used in combi-
nation with standard therapy in order to target both
CAFs and cancer cells. For instance, sibrotuzumab is
an antibody that inactivates the CAF marker FAP.
Clinical trials have failed, however, to show clinical
efficacy in metastatic colorectal cancer.52
Furthermore, the tumour microenvironment exerts
an important influence on therapy response. Previous
preclinical and clinical studies showed that tumours
with high stromal content become resistant to ther-
apy. Lotti et al. demonstrated that chemotherapy-
treated CAFs promoted tumour-initiating cells and
© 2018 John Wiley & Sons Ltd, Histopathology, 73, 197–206.
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tumour growth in vivo.53 Similar results were found
in endothelial cells able to induce chemoresistance in
CRC cells.54 Consistent with the preclinical studies, a
correlation was found between poor prognosis and
increased amount of stroma in tumours pretreated
with radio- and/or chemotherapy.55,56 Song et al.
showed in a randomized clinical trial that CRC
patients at stages II–III of the CMS4 subtype did not
benefit from adjuvant oxaliplatin.57 Furthermore, a
retrospective study showed that patients with rectal
cancer of the CMS4 subtype had a poor response to
radiotherapy.26
Acquiring further insights into the complexity
between the cancer cells and its microenvironment
may provide novel tumour stroma-targeted therapy
as well as a clearer understanding of drug resistance.
TSR in solid epithelial tumours
The prognostic value of the TSR reaches further than
colon cancer; it is also observed in a range of other
different solid epithelial tumours.13–24 Recently, an
elaborated meta-analysis was conducted on 14 stud-
ies with 4238 patients to study the TSR on prognosis
in solid tumours. The authors identified that stroma-
high tumours were associated with worse overall sur-
vival and disease-free survival in colon cancer, breast
cancer, ovarian cancer, non-small-cell lung cancer,
nasopharyngeal cancer, oesophageal cancer and hep-
atocellular cancer.58 However, two papers studying
early stage cervical cancer found contradictory
results.17,22 The study by Pongsuvareeyakul et al. did
not reveal an independent prognostic value of the
TSR.22 This might be explained by the fact that this
study had a small number of recurrences and death,
which might reduce the ability of statistical analysis.
Furthermore, in contrast to the study by Liu et al.,
Pongsuvareeyakul et al. only included cervical adeno-
carcinoma patients and no squamous carcinoma
patients, suggesting that histological types of cervical
cancer might have a different impact on prognosis.
This should be investigated further. Similar to colon
cancer, the TSR method also has a high interobserver
agreement in a variety of studies of other epithelial
cancer types (Table 2).13–22,59 The use of the TSR
across tumour types emphasizes the robustness of the
method.
Daily diagnostic practice
Many prognostic biomarkers have been, or are cur-
rently, under investigation for implementation in rou-
tine clinical diagnostics. For instance, mutations in
BRAF and KRAS and the microsatellite instability
(MSI)-status are well-known prognostic and predictive
markers used in the clinic to characterise colorectal
tumours and determining specific treatment. Besides
its prognostic value, the TSR might be used as an
additional high-risk factor to select patients for adju-
vant therapy. We believe that stroma-high tumours
Table 2. Characteristics of tumour stroma studies in other types of epithelial cancers, which adapted the method described
in this paper and reported an interobserver variation
Study Number of patients Stage Type of cancer Interobserver variation
Courrech Staal et al., 2010 93 I–IV Oesophageal Κ = 0.84
De Kruijf et al., 2011 574 I–III Breast Κ = 0.85
Moorman et al., 2012 124 I–III Breast (triple-negative) Κ = 0.74
Dekker et al., 2013 403 I–III Breast Κ = 0.80
Wang et al., 2013 95 I–III Oesophageal Κ = 0.84
Gujam et al., 2014 361 I–III Breast Κ = 0.83
Liu et al., 2014 184 I–II Cervical Κ = 0.81
Zhang et al., 2014 93 I–IV Nasopharyngeal Κ = 0.85
Lv et al., 2015 300 I–IV Liver Κ = 0.87
Pongsuvareeyakul et al., 2015 131 I–II Cervical Κ = 0.78
Li et al., 2017 51 II–IV Gallbladder Κ = 0.85
© 2018 John Wiley & Sons Ltd, Histopathology, 73, 197–206.
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should be treated accordingly. However, there is as
yet no information how stroma-high tumours will
respond to adjuvant therapy.
Potential prognostic markers as the Immuno-
score,60 tumour budding61 and the CMS classifica-
tion6 have been proposed for implementation in daily
practice. In order for a biomarker to be implemented
into the clinic it has to show clinical relevance. Also,
feasibility and ease to use are important factors.
In our opinion, it is time to combine biomarkers
which integrate different aspects of the tumour biol-
ogy, including the interaction with the tumour
microenvironment. In addition to the clear evidence
of the prognostic value of the TSR, a critical advan-
tage of the TSR lays within its simplicity, repro-
ducibility and low costs. Therefore, the TSR method
is applicable for all pathology centres.
Further research
A U T O M A T I O N
An automated scoring method of the TSR is under
development, which will lead to a standardized proto-
col with optimal reproducibility. In 2014, Bianconi
et al. showed the possibility to discriminate between
tumour epithelial and stroma in colorectal cancer
patients, with an accuracy of almost 97% using an
automated image analysis system. However, this
study was based on an image database that consisted
of small parts of tissue samples instead of whole
tumour slides. The challenge for automated scoring
will be to detect the areas containing the highest
amount of stroma using whole slide imaging.62 A dis-
advantage of an automated scoring method is the
increase of cost and time due to the acquirement of a
slide scanner and software. However, digitalization of
the pathology workflow asks for automated scoring of
the TSR. Therefore, the automation of the method is
almost inevitable.
P R O S P E C T I V E M U L T I C E N T R E S T U D Y
The TSR has been discussed by the TNM Evaluation
Committee (UICC) and the College of American
Pathologists (CAP), who stated that it has the poten-
tial to be included in the TNM staging algorithm. In
order to reach this, the reproducibility of the TSR
method is currently being validated in a large Euro-
pean multicentre study. In parallel, a prospective
cohort will be used to validate the potential value of
the TSR as a selection tool for high-risk patients.
Conclusion
It is well established that the interaction between
cancer cells and its microenvironment is involved in
tumour progression and metastasis. The TSR proba-
bly reflects this interaction. CAFs constitute the most
abundant cell type in the tumour stroma, and this
cell population releases a cascade of growth factors
promoting tumorigenesis. The tumour stroma is able
to induce stem cell-like properties and EMT in colon
cancer cells, making the cancer cell acquire prometa-
static capacities. Acquiring further insights into the
complexity between the cancer cells and its microen-
vironment may provide novel tumour stroma-tar-
geted therapy and understand drug resistance.
Given the current understanding of the tumour
stroma, colon cancer should not be categorized based
solely on tumour cell characteristics, but also accord-
ing to the tumour microenvironment. The TSR has
been proved to have prognostic relevance in colon
cancer patients. Combining this knowledge, it would
suggest that the TSR should be added to the current
TNM classification. Owing to its simplicity, reliability
and low costs, the TSR score can be implemented
with little effort in current routine diagnostics of the
pathologist.
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